- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | INDP-Aktie erreicht 52-Wochen-Tief bei 0,81 US-Dollar | 1 | Investing.com Deutsch | ||
| Do | INDP stock touches 52-week low at $0.81 amid market challenges | 2 | Investing.com | ||
| Mo | Indaptus Therapeutics files to sell 1.94M shares of common stock | 4 | Seeking Alpha | ||
| Mo | Indaptus Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 22.11. | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.11. | Indaptus sichert sich 2,1 Millionen US-Dollar durch Aktien- und Optionsscheinverkauf | 6 | Investing.com Deutsch | ||
| 22.11. | Indaptus Therapeutics announces $2.135M registered direct offering | 1 | Seeking Alpha | ||
| INDAPTUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.11. | Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 22.11. | Indaptus secures $2.1 million through stock and warrants sale | 1 | Investing.com | ||
| 19.11. | INDP stock touches 52-week low at $1.02 amid market challenges | 1 | Investing.com | ||
| 19.11. | INDP-Aktie erreicht 52-Wochen-Tief bei 1,02 US-Dollar | 2 | Investing.com Deutsch | ||
| 12.11. | Indaptus Therapeutics GAAP EPS of -$0.32 | 1 | Seeking Alpha | ||
| 12.11. | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology | 2 | GlobeNewswire (USA) | ||
| 07.11. | Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting | 76 | GlobeNewswire (Europe) | NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer... ► Artikel lesen | |
| 22.10. | Indaptus Therapeutics geht Partnerschaft mit BeiGene für Krebsstudie ein | 12 | Investing.com Deutsch | ||
| 22.10. | Indaptus Therapeutics partners with BeiGene for cancer study | 1 | Investing.com | ||
| 22.10. | Indaptus Therapeutics signs clinical supply agreement with Beigene | 2 | Seeking Alpha | ||
| 22.10. | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10. | Indaptus Therapeutics maintains steady target with Buy rating | 2 | Investing.com |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,428 | +29,70 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,240 | 0,00 % | Ginkgo Bioworks (NYSE:DNA) Shares Gap Down - Here's Why | ||
| RECURSION PHARMACEUTICALS | 7,660 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,700 | -0,38 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,000 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,930 | +2,42 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,900 | 0,00 % | Assertio Holdings, Inc.: Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study |
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,890 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 6,060 | 0,00 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,420 | +0,54 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,780 | 0,00 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,305 | +9,27 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| BIO-PATH | 1,330 | 0,00 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,270 | +1,42 % | Where Will Summit Therapeutics Be in 5 Years? |
Das Unternehmen INDAPTUS THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,850 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INDAPTUS THERAPEUTICS INC finden Sie auf Wallstreet Online.
